CRISPR Stock Volatility

CRSP
 Stock
  

USD 68.24  1.28  1.91%   

We consider CRISPR Therapeutics very steady. CRISPR Therapeutics secures Sharpe Ratio (or Efficiency) of 0.0314, which signifies that the company had 0.0314% of return per unit of return volatility over the last 3 months. Our approach to foreseeing the volatility of a stock is to use all available market data together with stock-specific technical indicators that cannot be diversified away. We have found twenty-eight technical indicators for CRISPR Therapeutics AG, which you can use to evaluate the future volatility of the firm. Please confirm CRISPR Therapeutics Risk Adjusted Performance of 0.0426, semi deviation of 5.39, and Mean Deviation of 4.41 to double-check if the risk estimate we provide is consistent with the expected return of 0.17%.
  
Refresh
CRISPR Therapeutics Stock volatility depicts how high the prices fluctuate around the mean (or its average) price. In other words, it is a statistical measure of the distribution of CRISPR daily returns, and it is calculated using variance and standard deviation. We also use CRISPR's beta, its sensitivity to the market, as well as its odds of financial distress to provide a more practical estimation of CRISPR Therapeutics volatility.

540 Days Market Risk

Very steady

Chance of Distress

Very Low

540 Days Economic Sensitivity

Actively responds to the market
Since volatility provides investors with entry points to take advantage of stock prices, companies, such as CRISPR Therapeutics can benefit from it. Downward market volatility can be a perfect environment for investors who play the long game. Here, they may decide to buy additional stocks of CRISPR Therapeutics at lower prices. For example, an investor can purchase CRISPR stock that has halved in price over a short period. This will lower your average cost per share, thereby improving your portfolio's performance when the markets normalize. Similarly, when the prices of CRISPR Therapeutics' stock rises, investors can sell out and invest the proceeds in other equities with better opportunities. Investing when markets are volatile with better valuations will accord both investors and companies the opportunity to generate better long-term returns.

CRISPR Therapeutics Market Sensitivity And Downside Risk

CRISPR Therapeutics' beta coefficient measures the volatility of CRISPR stock compared to the systematic risk of the entire stock market represented by your selected benchmark. In mathematical terms, beta represents the slope of the line through a regression of data points where each of these points represents CRISPR stock's returns against your selected market. In other words, CRISPR Therapeutics's beta of 1.69 provides an investor with an approximation of how much risk CRISPR Therapeutics stock can potentially add to one of your existing portfolios.
Let's try to break down what CRISPR's beta means in this case. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, CRISPR Therapeutics will likely underperform.
3 Months Beta |Analyze CRISPR Therapeutics Demand Trend
Check current 90 days CRISPR Therapeutics correlation with market (DOW)

CRISPR Beta

    
  1.69  
CRISPR standard deviation measures the daily dispersion of prices over your selected time horizon relative to its mean. Typical volatile equity has a high standard deviation, while the deviation of a stable instrument is usually low. As a downside, the standard deviation calculates all uncertainty as risk, even when it is in your favor, such as above-average returns.

Standard Deviation

    
  5.46  
It is essential to understand the difference between upside risk (as represented by CRISPR Therapeutics's standard deviation) and the downside risk, which can be measured by semi-deviation or downside deviation of CRISPR Therapeutics stock's daily returns or price. Since the actual investment returns on holding a position in CRISPR Therapeutics stock tend to have a non-normal distribution, there will be different probabilities for losses than for gains. The likelihood of losses is reflected in the downside risk of an investment in CRISPR Therapeutics.

CRISPR Therapeutics Implied Volatility

    
  89.81  
CRISPR Therapeutics' implied volatility exposes the market's sentiment of CRISPR Therapeutics AG stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if CRISPR Therapeutics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that CRISPR Therapeutics stock will not fluctuate a lot when CRISPR Therapeutics' options are near their expiration.

CRISPR Therapeutics Stock Volatility Analysis

Volatility refers to the frequency at which CRISPR Therapeutics stock price increases or decreases within a specified period. These fluctuations usually indicate the level of risk that's associated with CRISPR Therapeutics' price changes. Investors will then calculate the volatility of CRISPR Therapeutics' stock to predict their future moves. A stock that has erratic price changes quickly hits new highs, and lows are considered highly volatile. A stock with relatively stable price changes has low volatility. A highly volatile stock is riskier, but the risk cuts both ways. Investing in highly volatile security can either be highly successful, or you may experience significant failure. There are two main types of CRISPR Therapeutics' volatility:

Historical Volatility

This type of stock volatility measures CRISPR Therapeutics' fluctuations based on previous trends. It's commonly used to predict CRISPR Therapeutics' future behavior based on its past. However, it cannot conclusively determine the future direction of the stock.

Implied Volatility

This type of volatility provides a positive outlook on future price fluctuations for CRISPR Therapeutics' current market price. This means that the stock will return to its initially predicted market price.
Transformation
The output start index for this execution was zero with a total number of output elements of sixty-one. CRISPR Therapeutics Typical Price indicator is an average of each day price and can be used instead of closing price when creating different CRISPR Therapeutics moving average lines.
.

CRISPR Therapeutics Projected Return Density Against Market

Given the investment horizon of 90 days the stock has the beta coefficient of 1.6868 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, CRISPR Therapeutics will likely underperform.
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to CRISPR Therapeutics or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that CRISPR Therapeutics stock's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a CRISPR stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
The company has an alpha of 0.3794, implying that it can generate a 0.38 percent excess return over DOW after adjusting for the inherited market risk (beta).
 Predicted Return Density 
      Returns 
CRISPR Therapeutics' volatility is measured either by using standard deviation or beta. Standard deviation will reflect the average amount of how CRISPR Therapeutics stock's price will differ from the mean after some time.To get its calculation, you should first determine the mean price during the specified period then subtract that from each price point.

What Drives a Company's Stock Price Volatility?

Several factors can influence a company's stock volatility:

Industry

Specific events can influence volatility within a particular industry. For instance, a significant weather upheaval in a crucial oil-production site may cause oil prices to increase in the oil sector. The direct result will be the rise in the stock price of oil distribution companies. Similarly, any government regulation in a specific industry could negatively influence stock prices due to increased regulations on compliance that may impact the company's future earnings and growth.

Political and Economic environment

When governments make significant decisions regarding trade agreements, policies, and legislation regarding specific industries, they will influence stock prices. Everything from speeches to elections may influence investors, who can directly influence the stock prices in any particular industry. The prevailing economic situation also plays a significant role in stock prices. When the economy is doing well, investors will have a positive reaction and hence, better stock prices and vice versa.

The Company's Performance

Sometimes volatility will only affect an individual company. For example, a revolutionary product launch or strong earnings report may attract many investors to purchase the company. This positive attention will raise the company's stock price. In contrast, product recalls and data breaches may negatively influence a company's stock prices.

CRISPR Therapeutics Stock Risk Measures

Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to CRISPR Therapeutics or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that CRISPR Therapeutics stock's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a CRISPR stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
Given the investment horizon of 90 days the coefficient of variation of CRISPR Therapeutics is 3180.34. The daily returns are distributed with a variance of 29.78 and standard deviation of 5.46. The mean deviation of CRISPR Therapeutics AG is currently at 4.36. For similar time horizon, the selected benchmark (DOW) has volatility of 1.42
α
Alpha over DOW
0.38
β
Beta against DOW1.69
σ
Overall volatility
5.46
Ir
Information ratio 0.05

CRISPR Therapeutics Stock Return Volatility

CRISPR Therapeutics historical daily return volatility represents how much CRISPR Therapeutics stock's price daily returns swing around its mean daily price change - it is a statistical measure of its dispersion of returns. The firm inherits 5.4575% risk (volatility on return distribution) over the 90 days horizon. By contrast, DOW inherits 1.4314% risk (volatility on return distribution) over the 90 days horizon.
 Performance (%) 
      Timeline 

About CRISPR Therapeutics Volatility

Volatility is a rate at which the price of CRISPR Therapeutics or any other equity instrument increases or decreases for a given set of returns. It is measured by calculating the standard deviation of the annualized returns over a given period of time and shows the range to which the price of CRISPR Therapeutics may increase or decrease. In other words, similar to CRISPR's beta indicator, it measures the risk of CRISPR Therapeutics and helps estimate the fluctuations that may happen in a short period of time. So if prices of CRISPR Therapeutics fluctuate rapidly in a short time span, it is termed to have high volatility, and if it swings slowly in a more extended period, it is understood to have low volatility.
Please read more on our technical analysis page.
Last ReportedProjected for 2022
Market Capitalization5.8 B5.3 B
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats CRISPR-associated protein 9 platform. Its CRISPRCas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The companys lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patients hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics Investment Opportunity

CRISPR Therapeutics AG has a volatility of 5.46 and is 3.82 times more volatile than DOW. 47  of all equities and portfolios are less risky than CRISPR Therapeutics. Compared to the overall equity markets, volatility of historical daily returns of CRISPR Therapeutics AG is lower than 47 () of all global equities and portfolios over the last 90 days. Use CRISPR Therapeutics AG to enhance the returns of your portfolios. The stock experiences a large bullish trend. Check odds of CRISPR Therapeutics to be traded at $75.06 in 90 days. . Let's try to break down what CRISPR's beta means in this case. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, CRISPR Therapeutics will likely underperform.

Very weak diversification

The correlation between CRISPR Therapeutics AG and DJI is Very weak diversification for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding CRISPR Therapeutics AG and DJI in the same portfolio, assuming nothing else is changed.

CRISPR Therapeutics Additional Risk Indicators

The analysis of CRISPR Therapeutics' secondary risk indicators is one of the essential steps in making a buy or sell decision. The process involves identifying the amount of risk involved in CRISPR Therapeutics' investment and either accepting that risk or mitigating it. Along with some common measures of CRISPR Therapeutics stock risk such as standard deviation, beta, or value at risk, we also provide a set of secondary indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
Risk Adjusted Performance0.0426
Market Risk Adjusted Performance0.0838
Mean Deviation4.41
Semi Deviation5.39
Downside Deviation5.57
Coefficient Of Variation4042.45
Standard Deviation5.44
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential stock investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.

CRISPR Therapeutics Suggested Diversification Pairs

Pair trading is one of the very effective strategies used by professional day traders and hedge funds capitalizing on short-time and mid-term market inefficiencies. The approach is based on the fact that the ratio of prices of two correlating shares is long-term stable and oscillates around the average value. If the correlation ratio comes outside the common area, you can speculate with a high success rate that the ratio will return to the mean value and collect a profit.
Chevron Corp vs. CRISPR Therapeutics
Northrop Grumman vs. CRISPR Therapeutics
Teucrium Corn vs. CRISPR Therapeutics
Cincinnati Financial vs. CRISPR Therapeutics
Home Depot vs. CRISPR Therapeutics
Merck vs. CRISPR Therapeutics
Conagra Brands vs. CRISPR Therapeutics
Micron Technology vs. CRISPR Therapeutics
The effect of pair diversification on risk is to reduce it, but we should note this doesn't apply to all risk types. When we trade pairs against CRISPR Therapeutics as a counterpart, there is always some inherent risk that will never be diversified away no matter what. This volatility limits the effect of tactical diversification using pair trading. CRISPR Therapeutics' systematic risk is the inherent uncertainty of the entire market, and therefore cannot be mitigated even by pair-trading it against the equity that is not highly correlated to it. On the other hand, CRISPR Therapeutics' unsystematic risk describes the types of risk that we can protect against, at least to some degree, by selecting a matching pair that is not perfectly correlated to CRISPR Therapeutics AG.
Continue to Trending Equities. Note that the CRISPR Therapeutics information on this page should be used as a complementary analysis to other CRISPR Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.

Complementary Tools for CRISPR Stock analysis

When running CRISPR Therapeutics price analysis, check to measure CRISPR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CRISPR Therapeutics is operating at the current time. Most of CRISPR Therapeutics' value examination focuses on studying past and present price action to predict the probability of CRISPR Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move CRISPR Therapeutics' price. Additionally, you may evaluate how the addition of CRISPR Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Is CRISPR Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CRISPR Therapeutics. If investors know CRISPR will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CRISPR Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
5.2 B
Quarterly Revenue Growth YOY
0.74
Return On Assets
0.0855
Return On Equity
0.15
The market value of CRISPR Therapeutics is measured differently than its book value, which is the value of CRISPR that is recorded on the company's balance sheet. Investors also form their own opinion of CRISPR Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CRISPR Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CRISPR Therapeutics' market value can be influenced by many factors that don't directly affect CRISPR Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CRISPR Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine CRISPR Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CRISPR Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.